三水合艾司奥美拉唑镁反应结晶过程晶型控制

doi:10.3976/j.issn.1002-4026.2022.03.017

山东科学 ›› 2022, Vol. 35 ›› Issue (3): 138-144.doi: 10.3976/j.issn.1002-4026.2022.03.017

• 其他研究论文 • 上一篇

三水合艾司奥美拉唑镁反应结晶过程晶型控制

高绪洁^1,a^1b(),李洪程²,国建辉²,于帅^1,a^1,b^2,³,薛富民^1,a^1,b^*()

1.齐鲁工业大学(山东省科学院) a.山东省分析测试中心;b.药学院,山东济南 250014
2.寿光富康制药有限公司,山东寿光 262700
3.复旦大学药学院,上海 201203

收稿日期:2021-05-31 出版日期:2022-06-20 发布日期:2022-06-10
通信作者: 薛富民 E-mail:10431200323@stu.qlu.edu.cn;xuefumin@qlu.edu.cn
作者简介:高绪洁(1996—),女,硕士研究生,研究方向为药物结晶过程控制。E-mail: 10431200323@stu.qlu.edu.cn
基金资助:
山东省重大创新工程(2020CXGC010506);山东省重大创新工程(2021CXGC010514);山东省重大创新工程(2021CXGC010811);山东省自然科学基金(ZR2020QB177);齐鲁工业大学科教产融合试点工程(2020KJC-ZD09);山东省中央领导地方科技发展基金(YDZX2021054)

Crystal form control of the reactive crystallization process of esomeprazole magnesium trihydrate

GAO Xu-jie^1,a^1b(),LI Hong-cheng²,GUO Jian-hui²,YU Shuai^1,a^1,b^2,³,XUE Fu-min^1,a^1,b^*()

1. a. Shandong Analysis and Test Center; b. School of Pharmaceutical Sciences, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250014, China
2. Shouguang Fukang Pharmaceutical Co., Ltd.,Shouguang 262700, China
3. School of Pharmacy, Fudan University, Shanghai 201203, China

Received:2021-05-31 Online:2022-06-20 Published:2022-06-10
Contact: Fu-min XUE E-mail:10431200323@stu.qlu.edu.cn;xuefumin@qlu.edu.cn

摘要/Abstract

摘要：

对三水合艾司奥美拉唑镁制备过程中晶型控制进行研究,同时对产物的粒度分布等性质进行了工艺优化实验。通过X射线粉末衍射表征产物晶型,借助于二维在线成像系统监测三水合艾司奥美拉唑镁反应结晶过程中的晶体形貌变化,运用马尔文激光粒度仪辅助监测晶体的粒度分布变化。考察了结晶温度、反应物的浓度等因素对三水合艾司奥美拉唑镁晶型与晶习的影响。结果表明,三水合艾司奥美拉唑镁结晶方式为球形结晶,结晶温度是影响晶型的关键因素,优化后的结晶温度为25 ℃。优化后的工艺可以制备晶型固定、粒度分布均匀、平均粒度大的三水合艾司奥美拉唑镁药物颗粒。

关键词: 三水合艾司奥美拉唑镁, 晶型控制, 反应结晶, 粒度

Abstract:

Herein, esomeprazole magnesium trihydrate was prepared and its crystal form was controlled. Moreover, the properties of the product, such as the particle size distribution, were optimized. X-ray powder diffraction was used to characterize the crystal shape of the product. A two-dimensional online imaging system was employed to monitor changes in the crystal morphology during the reactive crystallization of esomeprazole magnesium trihydrate. A Marvin laser particle size analyzer was used to monitor changes in the particle size distribution. The effects of the crystallization temperature, reactant concentration, on the crystal form and mophorology of esomeprazole trihydrate magnesium were investigated. Results show that the crystallization mode of esomeprazole magnesium trihydrate is spherical and the crystallization temperature is the key factor affecting the crystal shape. The optimized reaction temperature was 25 ℃. Using the optimized process, drug particles of esomeprazole magnesium trihydrate with a fixed crystal shape, uniform particle size distribution, and large average particle size can be synthesized.

Key words: :esomeprazole magnesium trihydrate, crystal shape control, reactive crystallization, particle size

中图分类号:

R913

高绪洁,李洪程,国建辉,于帅,薛富民. 三水合艾司奥美拉唑镁反应结晶过程晶型控制[J]. 山东科学, 2022, 35(3): 138-144.

GAO Xu-jie,LI Hong-cheng,GUO Jian-hui,YU Shuai,XUE Fu-min. Crystal form control of the reactive crystallization process of esomeprazole magnesium trihydrate[J]. Shandong Science, 2022, 35(3): 138-144.

图/表 8

图1

图2

图3

图4

图5

图6

图7

图8

参考文献 14

[1]	BHESANIYA K, BALUJA S. Solubility of esomeprazole magnesium trihydrate in alcohols at temperatures from 298.15 to 318.15 K[J]. Russian Journal of Physical Chemistry A, 2013, 87(13): 2187-2190. DOI: 10.1134/S0036024413130062. doi: 10.1134/S0036024413130062
[2]	段洪东, 赵忠熙, 何淑旺, 等. 一种埃索美拉唑镁三水合物的制备方法: CN111072633A[P]. 2020-04-28.
[3]	HANNA C, ANDERS K, ANDERS M, et al. Novel form of S-omeprazole: US 20050075369[P]. 2005-04-07.
[4]	CASAR T, RENATA. PROCESS FORThe preparation of S-omeprazole magnesium in a stable form: EP20080160826[P]. 2010-01-27.
[5]	CHOUIPPE S, SCHNEIDER J M, TAUVEL G. Precursor phase and use thereof for preparing the magnesium tetrahydrate salt of an omeprazole enantiomer: EP2385046[P]. 2012-09-19.
[6]	BECHTLOFF B, NORDHOFF S, ULRICH J. Pseudopolymorphs in industrial use[J]. Crystal Research and Technology, 2001, 36(12): 1315. DOI: 10.1002/1521-4079(200112)36:12<1315:aid-crat1315>3.0.co;2-r. doi: 10.1002/1521-4079(200112)36:12<1315:aid-crat1315>3.0.co;2-r
[7]	林青, 陆杰, 周迅, 等. 埃索美拉唑镁多晶型的制备、表征及相互转化[J]. 中国医药工业杂志, 2014, 45(4): 377-380. DOI: 10.16522/j.cnki.cjph.2014.04.025. doi: 10.16522/j.cnki.cjph.2014.04.025
[8]	修利军. 埃索美拉唑治疗反流性食管炎的临床疗效分析[J]. 中国冶金工业医学杂志, 2018, 35(1): 17-18. DOI: 10.13586/j.cnki.yjyx1984.2018.01.012. doi: 10.13586/j.cnki.yjyx1984.2018.01.012
[9]	SKIENEH J, KHALILI NAJAFABADI B, HORNE S, et al. Crystallization ofesomeprazole magnesium water/butanol solvate[J]. Molecules (Basel, Switzerland), 2016, 21(4): 544. DOI: 10.3390/molecules21040544. doi: 10.3390/molecules21040544
[10]	周新波, 吴素香, 孙梦莹, 等. 埃索美拉唑镁盐多晶型的X-射线粉末衍射定量分析[J]. 药物分析杂志, 2015, 35(11): 1934-1939. DOI: 10.16155/j.0254-1793.2015.11.12. doi: 10.16155/j.0254-1793.2015.11.12
[11]	OLBE L, CARLSSON E, LINDBERG P. A proton-pump inhibitor expedition: The case histories of omeprazole and esomeprazole[J]. Nature Reviews Drug Discovery, 2003, 2(2): 132-139. DOI: 10.1038/nrd1010. doi: 10.1038/nrd1010
[12]	陈桂良, 李君婵, 彭兴盛, 等. 药物晶型及其质量控制[J]. 药物分析杂志, 2012, 32(8): 1503-1508. DOI: 10.16155/j.0254-1793.2012.08.003. doi: 10.16155/j.0254-1793.2012.08.003
[13]	龚俊波, 王琦, 董伟兵, 等. 药物晶型转化与控制的研究进展[J]. 化工学报, 2013, 64(2): 385-392. DOI: 10.3969/j.issn.0438-1157.2013.02.001. doi: 10.3969/j.issn.0438-1157.2013.02.001
[14]	科顿·H, 克隆斯特伦·A, 马特松·A, 等. 新型S-奥美拉唑: CN1161351C[P]. 2004-08-11.

三水合艾司奥美拉唑镁反应结晶过程晶型控制

Crystal form control of the reactive crystallization process of esomeprazole magnesium trihydrate

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

图/表 8

参考文献 14

相关文章 2

Metrics

本文评价

推荐阅读 0

[1]	周迎梅. DBA、SDBS对渣油热反应中相分离及生焦粒度的影响[J]. 山东科学, 2018, 31(4): 72-78.
[2]	胡玉芬. 钢渣免烧砖碳化影响因素研究[J]. 山东科学, 2015, 28(1): 97-101.